CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…
88,020€
-2,28%
Echtzeit-Aktienkurs Incyte Corp.
Bid:
Ask:
Nachrichten zur Incyte Corp. Aktie
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incytes (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.…